Search
This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(0)
- Annex to CHMP highlights(0)
- Annual Report(0)
- Application withdrawal assessment report(0)
- Committee meeting report(0)
- COVID-19 vaccine safety update(0)
- Direct healthcare professional communication(0)
- EPAR - All authorised presentations(0)
- EPAR - Amended Product Information(0)
- EPAR - Assessment report - Variation(0)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(0)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(0)
- EPAR - Conditions imposed on member states for safe and effective use(0)
- EPAR - Overview(0)
- EPAR - Paediatric investigation plan compliance statement(0)
- EPAR - Procedural steps taken and scientific information after authorisation(0)
- EPAR - Procedural steps taken before authorisation(0)
- EPAR - Product Information(0)
- EPAR - Public assessment report(0)
- EPAR - Risk-management-plan summary(0)
- EPAR - Risk management plan(0)
- EPAR - Scientific conclusion(0)
- EPAR - Scientific Discussion(0)
- EPAR - Scientific Discussion - Variation(0)
- EPAR - Steps taken after authorisation when a cutoff date has been used(0)
- Herbal - Call for data(0)
- Herbal - Herbal monograph(0)
- Herbal - HMPC assessment report(0)
- Herbal - HMPC opinion on a European Union herbal monograph(0)
- Herbal - List of references supporting the assessment report(0)
- Herbal - Overview of comments received during consultation(0)
- Herbal - Summary of assessment report for the public(0)
- Herbal – European Union herbal monograph(0)
- Herbal – European Union list entry(0)
- Leaflet(0)
- Maximum Residue Limits - Divergent opinion(0)
- Maximum Residue Limits - Opinion(0)
- Maximum Residue Limits - Report(0)
- Maximum Residue Limits - Summary of opinion(0)
- Medicine QA(0)
- Medicines under additional monitoring(0)
- Minutes(0)
- Newsletter(0)
- Opinion on any scientific matter(0)
- Opinion outside EU - All presentations(0)
- Opinion outside EU - Assessment report - Variation(0)
- Opinion outside EU - Medicine questions and answers(0)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(0)
- Opinion outside EU - Procedural steps taken before opinion(0)
- Opinion outside EU - Product information(0)
- Opinion outside EU - Public assessment report(0)
- Opinion outside EU - Risk-management-plan summary(0)
- Opinion outside EU - Scientific discussion(0)
- Opinion outside EU - Summary for the public(0)
- Opinion outside EU - Summary of opinion(0)
- Opinion outside EU - Summary of opinion - Initial authorisation(0)
- Opinion outside EU - Withdrawal assessment report(0)
- Orphan designation(0)
- Orphan review(0)
- Other(0)
- Overview of comments(0)
- Periodic safety update single assessment(0)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(0)
- PIP - Paediatric-investigation-plan summary(0)
- PIP decision(0)
- Position statement(0)
- PRAC recommendation on signal(0)
- Presentation(0)
- Press Release(0)
- Procurement(0)
- Public Statement(0)
- Recommendation on medication errors(0)
- Recruitment(0)
- Referrals document(0)
- Regulatory and procedural guideline(0)
- Report(0)
- Scientific guideline(0)
- Standard Operating Procedure - SOP(0)
- Summary of opinion(0)
- Summary of opinion - Initial authorisation(0)
- Template or form(0)
- Withdrawal letter(0)
- Work Instruction - WIN(0)
- Work programme(0)
- (-)Advanced therapies(407)
- Antimicrobial resistance(48)
- Biologicals(24)
- Biosimilars(169)
- Brexit(30)
- Careers(4)
- Clinical trials(208)
- Compassionate use(4)
- Compliance and inspections(106)
- Corporate(70)
- COVID-19(471)
- Data on medicines(192)
- Early access(25)
- Fees(16)
- Generic and hybrid medicines(406)
- Governance(101)
- Innovation(283)
- Maximum residue limit(19)
- Medical devices(32)
- Medication error(7)
- Medicines(8232)
- Medicines for use outside the EU(34)
- Medicine shortages(224)
- Mpox(19)
- Paediatrics(3284)
- Parallel distribution(6)
- Pharmacovigilance(3116)
- Procurement(11)
- Product information(69)
- Quality of medicines(94)
- Rare diseases(3420)
- Referrals(401)
- Regulatory and procedural guidance(567)
- Research and development(232)
- Scientific advice(38)
- Scientific guidelines(1031)
- SME(64)
- Vaccines(398)
- Veterinary limited markets(15)
Search results (407)
European Medicines Agency, Amsterdam, the Netherlands
Start date:
19 March 2025
End date:
21 March 2025
EventHumanAdvanced therapiesInnovation
Authorities warn about unregulated products in the EU, including dendritic cell cancer therapies
13 March 2025
NewsHumanAdvanced therapies
Date of designation:
7 November 2008
Expired
Last updated:
7 March 2025
OrphanHuman
ex vivo expanded autologous human corneal epithelial cells containing stem cells
Stem Cell Transplantation, Corneal Diseases
Date of authorisation:
Revision:
12
Last updated:
7 March 2025
MedicineHumanAuthorised
Brexucabtagene autoleucel
Lymphoma, Mantle-Cell
Date of authorisation:
Revision:
10
Last updated:
3 March 2025
MedicineHumanAuthorised
spheroids of human autologous matrix-associated chondrocytes
Cartilage Diseases
Date of authorisation:
Revision:
9
Last updated:
3 March 2025
MedicineHumanAuthorised
beremagene geperpavec
Epidermolysis Bullosa Dystrophica
Opinion date:
Last updated:
28 February 2025
MedicineHumanOpinion
European Medicines Agency, Amsterdam, the Netherlands
Start date:
22 January 2025
End date:
24 January 2025
EventHumanAdvanced therapiesInnovation
ciltacabtagene autoleucel
Multiple Myeloma
Date of authorisation:
Revision:
9
Last updated:
25 February 2025
MedicineHumanAuthorised
lisocabtagene maraleucel
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Mediastinal Neoplasms
Date of authorisation:
Revision:
7
Last updated:
24 February 2025
MedicineHumanAuthorised